Role this area should play in the mHealth space |
---|
mHealth solutions have the great risk of hype and promise. Decision makers need to have evidence of which kinds of mHealth deliver health outcomes benefits, are acceptable to patients and to healthcare providers, and are cost-effective. Programme developers need firstly to be encouraged to adopt a methodological approach to their programme design and adoption model so that evaluation is possible. Secondly, they must be encouraged to invest in good quality evaluations. Thirdly they should be directed to adopt evaluation methods and metrics that align with other programmes, to enable accurate comparisons to be made and the evidence to be combined. |
Current challenges and limitations |
---|
|
What benefit could this bring to adopters of this innovation? |
---|
Programme developers will collect evidence to support the sustainability and scalability of their own programmes, and support the evidence base for future programs within their own geographical area and more broadly. |
How does it contribute to major EU policy priorities? (e.g. EHDS, COVID-19, DTHC etc.) |
This area of the Hub will help support evidence for EU policy priorities, such as DTHC. |
No post found
What is on the horizon? |
---|
There are no specific innovations forthcoming this area, except possibly the greater use of sensors to monitor the health and disease status of mHealth users, so that at least some of the empirical evaluation evidence can be collected automatically, with a minimal burden. |